On May 21, Mengke Pharmaceuticals (688373) announced that the company's new drug marketing authorization application for contezolidinone sodium for injection was accepted by the National Medical Products Administration. The drug is a Class 1 antibacterial drug of the oxazolidinone class independently developed by the company. The previous contezolidinone tablets were approved in 2021 for the treatment of complicated skin and soft tissue infections.

The sodium contezolizumab for injection applied for this time is a water-soluble prodrug of contezolizumab. Based on the background that the prodrug has been approved, the company has carried out relevant Phase III clinical trials and successfully achieved the primary efficacy endpoint. Although the new drug marketing authorization application has been accepted, the announcement mentioned that the application still needs to go through review, clinical trial site inspection and approval, and the time and results are uncertain, so it will not have a significant impact on the company's performance in the short term.

In the first quarter of 2025, Mengke Pharmaceutical achieved revenue of 33.22 million yuan and a net profit attributable to the parent of -61.63 million yuan.

https://finance.eastmoney.com/a/202505213410892912.html